Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Final ASCEND study data: Acalabrutinib beat standard of care for r/r CLL

Publish date:: October 23, 2020

Key clinical point: Acalabrutinib has favorable efficacy versus standard of care for relapsed or refractory chronic lymphocytic leukemia.

Major finding: The estimated 18-month progression-free survival was 82% versus 48% with acalabrutinib versus standard of care.

Study details: Final results from the phase 3 ASCEND trial of 310 patients.

Disclosures: This study was sponsored by Acerta Pharma. Dr. Ghia reported consulting or advisory roles, grant or research funding, and/or honoraria from a variety of pharmaceutical companies.

Citation:

Ghia P et al. SOHO 2020, Abstract CLL-091.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in CLL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Pigment traits, sun sensitivity associated with risk of non-Hodgkin lymphomas and chronic lymphocytic leukemia,

Ibrutinib associated with decreased circulating malignant cells and restored T-cell function in CLL patients,

Final ASCEND study data: Acalabrutinib beat standard of care for r/r CLL,

Meta-analysis: Acalabrutinib showed better PFS and OS than other frontline CLL therapies,